Orchid Pharma Ltd

Orchid Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 20 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 29 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of late August 2026. Despite a sharp day decline of 6.45%, the stock’s longer-term technical indicators suggest a cautiously optimistic outlook, supported by mixed signals from MACD, RSI, moving averages, and other momentum oscillators.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance, reflecting a nuanced change in market sentiment. Despite a recent decline of 2.95% in daily price, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes that investors should carefully analyse.

Orchid Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its overall outlook. This change is driven by improvements in quality metrics, tempered valuation concerns, mixed financial trends, and cautious technical signals. Despite recent challenges, the company’s long-term market-beating returns and institutional backing have contributed to this reassessment.

Orchid Pharma Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While key metrics such as return on equity (ROE) and return on capital employed (ROCE) remain modest, the company’s growth trajectory and debt profile reveal both encouraging and cautionary signals for investors navigating the Pharmaceuticals & Biotechnology sector.

Orchid Pharma Ltd experienced significant intraday weakness on 17 Aug 2026, with its stock price touching a low of Rs 942, marking a 10.04% decline from the previous close. The pharmaceutical company faced notable price pressure today, underperforming its sector and broader market indices amid heightened volatility and subdued market sentiment.

Surging to a fresh 52-week high of Rs 1130 on 11 Aug 2026, Orchid Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market with a 43.77% gain over the past year against the Sensex’s decline of 2.99%.

Orchid Pharma Ltd has experienced a notable shift in price momentum, with technical indicators signalling a transition from a mildly bullish to a bullish trend. The stock’s recent 7.17% day gain to ₹1,076.60, coupled with positive weekly and monthly technical signals, suggests renewed investor interest despite a modest Mojo Score of 44.0 and a Sell grade.

The Sensex edged up a modest 0.05% on 10 Aug 2026, while Orchid Pharma Ltd surged 7.33%, marking a standout session in the Pharmaceuticals & Biotechnology sector with a 7.61 percentage-point outperformance. This sharp intraday gain rewrites the short-term narrative for the small-cap stock, which has been on a three-day winning streak, accumulating a 9% return in that period.

Orchid Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock’s price action and technical indicators suggest a cautiously optimistic outlook amid ongoing market volatility.

Orchid Pharma Ltd has exhibited a notable shift in its technical momentum, transitioning from a mildly bullish stance to a more confident bullish trend. This change is underscored by a mix of positive signals from key technical indicators such as MACD, moving averages, and Bollinger Bands, despite some bearish nuances in the RSI on a weekly basis. Investors and analysts are closely monitoring these developments as the stock navigates a critical phase in its price trajectory.

Orchid Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day change of 0.18%, the stock’s technical parameters reveal a transition from a previously strong sell rating to a sell grade, underscoring evolving market sentiment and momentum dynamics.

Orchid Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.